This article is written with mental health and healthcare providers in mind. If you’re not a provider, you’re still welcome to read along; just know the content is tailored to a clinical perspective.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — think semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have changed the way we think about metabolic health and weight loss. But over the last few years, they’ve also become a cultural phenomena, sparking conversations in every corner of healthcare.
It’s not just patients with diabetes or obesity asking about these drugs anymore. Clinicians are fielding questions like: “Could GLP-1s help my depression?” or “What about microdosing GLP-1s for mood?” The answers, as so often in medicine, are nuanced — which is predictably challenging for patients.
A Meteoric Rise and a New Set of Questions
It’s hard to overstate how quickly GLP‑1 RA have moved from specialty clinics to everyday patient panels. Monthly prescribing rates for GLP‑1 receptor agonists grew by as much as 119% for Wegovy and over 80% for Ozempic in 20221, and overall prescriptions increased more than 400% from 2019 to 2023.2
GLP‑1 RAs are among the fastest‑growing medication classes in the US, with prescriptions surging not just for diabetes and weight management, but sometimes even off‑label for a wider array of complaints. The financial ripple is substantial, impacting individuals, employer healthcare plans, and the healthcare system itself.3,4
What’s behind the hype? Part of it is patient experience. Some describe unexpected improvements: increased motivation, reduced anxiety, or a sense of “mental clarity.” Add in the constant churn of media stories, celebrity endorsements, and social media buzz, and it’s no wonder both exam rooms and therapy sessions are filled with questions.
From Metabolic Roots to Psychiatric Hopes
The science behind GLP-1 RAs’ metabolic benefits is complex. These drugs bind receptors in the brain, gut, pancreas, and liver, leading to a range of effects, including appetite suppression, insulin secretion, delayed gastric emptying, inhibition of glucagon metabolism, and reduced inflammation in adipose tissue.5 The resulting improved glucose control and weight loss has a large number of downstream effects including such things as improved cardiovascular health and reduced risk of several cancers, among many others.
But mental health? That’s a newer and much more complicated frontier. Metabolic health and psychiatric health are deeply intertwined. Patients with depression, anxiety, and/or serious mental illness face higher rates of insulin resistance, obesity, and metabolic syndrome.6 Conversely, improvements in physical health can, and often do, support improvements in mood and function.
So when patients report feeling “brighter” or “more energetic” after starting a GLP-1, clinicians have reason to be curious, even as we stay rooted in the evidence.
What Do Clinical Trials Say About GLP-1s For Mood?
GLP-1s are not approved for depression, nor any psychiatric disorder. The largest, most rigorous trials have focused on metabolic endpoints like Hemoglobin A1C, weight, and cardiovascular outcomes. However, some have included depression and anxiety measures as secondary outcomes.
A 2024 meta-analysis reviewed five randomized controlled trials and one cohort study, and found a small but statistically significant reduction in depressive symptoms among adults treated with GLP-1 receptor agonists compared to controls. The effect size was modest – about a third of the effect found in antidepressant trials – and these studies primarily involved patients with metabolic conditions such as diabetes or obesity.7
Is this a direct pharmacological effect, or a byproduct of weight loss, improved energy, or positive expectations? That’s still an open question. Quality of life and subjective well-being measures often improve with physical improvements, but again, teasing apart drug effects from broader life changes is difficult.
There’s some evidence from preclinical studies including animal studies that show some promising mechanisms for a direct effect. For example, some studies show that GLP-1 RAs reduce neuroinflammation and oxidative stress in the brain, and it has long been known that inflammation and oxidative stress are potentially elevated in depression.8,9
In short, the data is suggestive, but far from conclusive. GLP-1s may offer some psychiatric benefit for select patients, but no trial yet supports their use as a stand-alone or first-line treatment for depression in patients with or without metabolic disease. Further, these benefits have to be considered alongside side effects of GLP-1s. Thus far, while these drugs generally seem to be safe, we do not fully know the long term side effects nor the challenges of stopping these medications once they have begun.
The Allure and Uncertainty of Microdosing
Patient forums, social media, and even some private clinics are now discussing “microdosing” GLP-1s for mood, attention, energy, and other off-label uses. However, this interest is far ahead of the evidence.10 There are no established dosing protocols, no controlled studies, and significant uncertainties about safety and cost. As with many supplement and off-label trends, it’s essential to meet patient curiosity with both empathy and honest information.
Ethics, Access, and Equity
Clinicians must also weigh the broader context. GLP-1s are currently expensive, often require ongoing use, and can create significant financial strain for both individual patients and the healthcare system. Even when prescribed for approved indications, insurance coverage is inconsistent — many plans require strict prior authorization, and some exclude coverage for weight loss or off-label uses entirely. This means patients may face unpredictable out-of-pocket costs or sudden discontinuation of treatment if coverage changes.
The growing interest in “microdosing” GLP-1s for mood, energy, or attention — driven by anecdotes and social media — adds another layer of complexity. Because there are no established protocols or robust clinical evidence supporting these off-label uses, insurers are especially unlikely to cover such prescriptions. As a result, patients exploring microdosing for mental health symptoms often pay entirely out-of-pocket, increasing the risk of financial hardship or medication interruption.
At the system level, widespread demand for GLP-1s outside of established indications could further strain pharmacy budgets and supply chains, potentially affecting access for those with diabetes or severe obesity. If GLP-1s become the next “boutique” treatment — more accessible to those with resources, connections, or privileged healthcare access — the risk is that existing disparities in metabolic and mental health care will only widen. As interest and experimentation grow, clinicians must be mindful of equity, resource stewardship, and the importance of clear, evidence-based guidance.
The Metabolic-Mood Connection: Why This Is a Frontier Worth Watching
If there’s a silver lining to the current conversation, it’s the renewed focus on just how intertwined metabolic health and mental health truly are. Mounting research shows that depression, chronic inflammation, weight regulation, and cardiovascular risk factors frequently overlap — not just in populations, but in the underlying biology of individual patients. For decades, these conditions were often treated separately, despite evidence that metabolic dysfunction and psychiatric symptoms can reinforce one another.
The effects of GLP-1 receptor agonists are just another example of this connection. As clinicians observe shifts in mood and well-being alongside improvements in metabolic measures, there’s growing recognition that targeting shared pathways — like inflammation, glucose regulation, and hormonal signaling — may influence both body and mind. This integrated view is encouraging a more holistic approach to patient care, moving beyond isolated symptom management.
What Clinicians Can Do Right Now
Clinicians now face a unique challenge: how to guide care when their patients are taking GLP-1s.
Here are our conclusions:
- If you are not obese and do not have diabetes or another medical disorder that would warrant taking these medications, there’s no reason to take them for a psychiatric reason.
- If you do have a condition such as obesity or diabetes, you can and should discuss these medications with your primary care doctor. You should be aware that they may have a secondary effect on your depression, and you don’t need to start an antidepressant concurrently. If your depression or anxiety remains after you are stable on this medication for a couple of months, you may consider an antidepressant with your psychiatric clinician.
- Microdosing has no evidence in its favor, and it’s not advised to engage in it without a clear benefit, because you would be exposing yourself to side effects, some of which may not yet be known.
As interest and research in GLP-1 receptor agonists expand beyond metabolic health and into psychiatry, clinicians are tasked with navigating uncertainty, fielding complex questions, and balancing hope with honest guidance. For now, the best approach is one rooted in evidence, transparency, and collaboration. By staying current and keeping patient care at the center, providers can help ensure that emerging therapies are considered thoughtfully, always prioritizing what’s best for each individual in a rapidly changing landscape.
FAQs About GLP-1s and Depression
Are GLP-1s approved for depression?
No. Their only approved indications currently are for diabetes and weight management.
What’s the evidence that GLP-1s help with mood?
Some clinical studies and meta-analyses report slight improvements in depressive symptoms for patients with metabolic conditions (such as type 2 diabetes or obesity) who take GLP-1s. Evidence for anxiety improvement is inconsistent and less robust. These findings are not sufficient to support use as a treatment for mood or anxiety disorders.
What if a patient on a GLP-1 for metabolic reasons reports improved mood or reduced anxiety?
If a patient prescribed a GLP-1 for metabolic reasons reports improved mood or reduced anxiety, it’s appropriate to track these changes alongside metabolic outcomes. In some cases, such improvement might mean that other psychiatric medications may not be necessary, or that they are given at a lower dose. However, it also means that when the GLP-1 is tapered or stopped, other psychiatric medications may have to be adjusted as well to compensate.
Are there risks to off-label or “microdosing” GLP-1s for mood?
Yes. There are no established protocols, clinical trials, or long-term safety data for using GLP-1s at low doses or for psychiatric purposes. Costs, insurance barriers, accessibility, and unknown adverse effects are all important considerations.
References:
- Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Watanabe, Jonathan H. et al. Journal of the American Pharmacists Association, Volume 64, Issue 1, 133 – 138 - KFF. Medicaid Coverage of and Spending on GLP-1s, 2024.
- National Conference of State Legislatures. Growth, Volume, Price: The Skinny on GLP-1 Medications, 2024.
- Hwang JH, Laiteerapong N, Huang ES, Mozaffarian D, Fendrick AM, Kim DD. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. JAMA Health Forum. 2025;6(4):e250905. doi:10.1001/jamahealthforum.2025.0905
- Moiz, Areesha et al. (2025). Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine, 138(6), 934 – 940. https://www.amjmed.com/article/S0002-9343(25)00059-2/fulltext
- Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder, and major depressive disorder: A systematic review and meta-analysis. World Psychiatry, 14(3), 339–347. https://doi.org/10.1002/wps.20252
- Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024). The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 32(1), 117–127. https://doi.org/10.1016/j.jagp.2023.08.010
- Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International journal of molecular sciences, 23(17), 9583. https://doi.org/10.3390/ijms23179583
- Roya, A., Dawson, V. L., & Dawson, T. M. (2025). From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics. Neurotherapeutics, Advance online publication. https://doi.org/10.1016/j.neurot.2025.e00712
- UCLA Health. GLP-1 microdosing is experimental and unauthorized, 2025.
